Despite Recent Setbacks, Merck's CV Pipeline Is Strong
This article was originally published in The Pink Sheet Daily
Executive SummaryThe Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.
You may also be interested in...
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.